Evaluation of the possibility of clinical application by surface dose measurement of ViewRay in MFW treatment

MFW 치료 시 ViewRay의 표면선량 측정에 따른 임상 적용 가능성 평가

  • Sun, Geo Jun (Department of Radiation Oncology, Seoul National University Hospital) ;
  • Son, Sang Jun (Department of Radiation Oncology, Seoul National University Hospital) ;
  • Lee, Yang Hoon (Department of Radiation Oncology, Seoul National University Hospital) ;
  • Lee, Je Hee (Department of Radiation Oncology, Seoul National University Hospital)
  • 선거준 (서울대학교병원 방사선종양학과) ;
  • 손상준 (서울대학교병원 방사선종양학과) ;
  • 이양훈 (서울대학교병원 방사선종양학과) ;
  • 이제희 (서울대학교병원 방사선종양학과)
  • Published : 2018.12.29

Abstract

Purpose : The purpose of this study is to evaluate clinical applicability of Co-60 ViewRay treatment plan to increase the skin dose in case of high skin dose is required such as Malignant Fungating Wound By measuring the presence / absence of Bolus application and skin dose by the treatment device and comparing it Materials and Methods : Nine inner measuring points of 2.5 cm lattice arrangement and all 13 measuring points including upper and lower left and right measuring points touching the chest and skin were marked. After CT was taken, each treatment plan was formulated through Eclipse and ViewRay-TPS, and a Fixed beam-IMRT treatment plan was formulated so that the left chest V2Gy=95 % is delivered. Before measurement QED detector was calibrated and the QED detector was positioned at the 13 measurement points displayed on Phantom and surface dose of each treatment planner was measured using 5 mm Bolus application using True-beam and View-ray before and after, measure three times and compare each before applying 5 mm Bolus. Results : The surface dose of the Co-60 ViewRay and the linear accelerator appeared at $76.8%{\pm}5.2%$ vs. $67.3{\pm}%7.5%$ and the surface dose after application of 5 mm Bolus was $87.6%{\pm}8.9%$ vs. $80.3%{\pm}10.2%$ It was measured at 10.2 % (p<0.001). Conclusion : As a result of the surface dose measurement of each treatment instrument, Co-60 ViewRay confirmed that the surface dose reached 95.6 % of 6 MV Linac with conventional 5 mm bolus, despite not using Bolus (p<0.001). Also, by utilizing magnetic resonance images for each treatment, it is possible to observe the change in the treatment site without the problem of exposure, it is easy to formulate an adaptive treatment plan and it is easy to secure the skin dose, so the size In the case of Malignant Fungating Wound patients who need fast skin changes and need high skin doses, Co-60 ViewRay is considered to be more useful than linear accelerators.

목 적 : Bolus 적용 유, 무와 치료기에 따른 피부 선량을 측정, 비교하여 Malignant Fungating Wound와 같이 높은 피부 선량을 요구하는 경우 피부 선량 증가 목적으로 Co-60 ViewRay 치료계획의 임상 적용 가능성을 검토하였다. 대상 및 방법 : 표면선량을 측정하기 위해 Rando phantom을 이용하여 좌측유방 중심부를 기준으로 2.5 cm 격자 배열의 9개의 내측 측정지점과, 유방과 피부와 접하는 상하, 좌우 4개의 외측 측정지점을 포함한 총 13개 측정지점을 표시하였다. CT를 촬영을 하여 Eclipse와 ViewRay-TPS를 통해 각각의 치료계획을 수립하였으며, 좌측유방 V2Gy = 95 %가 전달되도록 Fixed beam-IMRT 치료계획을 수립하였다. 측정 전 QED 검출기를 교정하였으며 Phantom에 표시된 13개의 측정지점에 QED 검출기를 위치시켜 각 치료계획 별 표면선량을 True-beam과 View-ray를 이용하여 5 mm Bolus 적용 전과 후, 각각 3회 측정하여 비교하였다. 결 과 : 5 mm Bolus를 적용 전 Co-60 Viewray와 선형가속기의 표면선량은 $76.8%{\pm}5.2%$ vs. $67.3%{\pm}7.5%$로 나타났으며, 5 mm Bolus 적용 후 표면선량은 각각 $87.6%{\pm}8.9%$ vs. $80.3%{\pm}10.2%$로 측정되었다(p<0.001). 결 론 : 각 치료기의 표면선량 측정결과, Co-60 ViewRay는 Bolus를 사용하지 않았음에도 불구하고 표면 선량이 일반 5 mm Bolus를 사용한 6 MV 선형가속기의 95.6 % 수준 달하는 것을 확인하였다(p<0.001). 또한 매 회 치료마다 자기공명영상을 이용하여 피폭 문제없이 치료 부위 변화를 관찰할 수 있어 적응형 치료계획을 수립하기 쉽고 피부 선량 확보가 수월하므로, 크기 변화가 빠르고 높은 피부선량을 요구하는 Malignant Fungating Wound 환자의 경우 Co-60 ViewRay가 선형가속기에 비해 유용할 것으로 사료된다.

Keywords

References

  1. Young, C.V. The effects of malodorous fungating malignant wounds on body image and quality of life. J Wound Care, 2005. 14(8): p. 359-62 https://doi.org/10.12968/jowc.2005.14.8.26827
  2. Grocott, P. and S. Cowley, The palliative manage ment of fungating malignant wounds-generalising from multiple-case study data using a system of reasoning. Int J Nurs Stud, 2001. 38(5): p. 533-45 https://doi.org/10.1016/S0020-7489(00)00098-5
  3. Grocott, P., The palliative management of fungating malignant wounds. J Wound Care, 2000.9(1): p. 4-9 https://doi.org/10.12968/jowc.2000.9.1.25942
  4. Mortimer, P., Management of skin problems: medical aspects, in Oxford Textbook of palliative medicine, D. Doyle, et al., Editors. 2003, Oxford University Press: Oxford
  5. Hallet, A. Fungating wounds. (85)Nurs Times. 1995; 91: 81-82
  6. Naylor, W. Part 1: Symptom control in the management of fungating wounds. (Available from) (Accessed November 18, 2005)
  7. Haisfield-Wolfe, M.E. Malignant cutaneous wounds: a management protocol. (62, 64-66)Ostomy Wound Manage. 1997; 43: 56-60
  8. Neal, K. Treating fungating lesions. (86)Nurs Times. 1991; 87: 84
  9. Mutic S, Dempsey JF. The ViewRay system: Magnetic resonance-guided and controlled radiotherapy. Seminars in radiation oncology: Elsevier 2014:196-99
  10. Yang Y, Cao M, Sheng K, et al. Longitudinal diffusion MRI for treatment response assessment: Preliminary experience using an MRI guided tricobalt 60 radiotherapy system. Medical physics. 2016;43(3):1369-73 https://doi.org/10.1118/1.4942381
  11. Wooten HO, Rodriguez V, Green O, et al. Benchmark IMRT evaluation of a Co-60 MRI-guided radiation therapy system. Radiotherapy and Oncology. 2015;114(3):402-5 https://doi.org/10.1016/j.radonc.2015.01.015
  12. Dempsey J, Dionne B, Fitzsimmons J, et al : Arealtime MRI guided external beam radiotherapy delivery system. Med Phys, 2006;22, 33-54
  13. Vincent S. Khoo,(F.R.A.C.R.), Elizabeth J. Adams,(M. Sc.), Frank Saran, M.D.James
  14. RaaijmakersA J E,Raaymakers B W and Lagendijk J J W 2005 Integrating a MRI scanner with a 6MV radiotherapy accelerator: dose increase at tissue-air interfaces in a lateral magnetic field due to returning electrons Phys.Med. Biol. 50